| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1.9K |
| Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1.1K |
| Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update | Hepatology International | 2017 | 955 |
| Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis | Journal of Thoracic Oncology | 2017 | 432 |
| Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review | Annals of Oncology | 2017 | 372 |
| Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies | Journal of Hepatology | 2017 | 321 |
| Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial | Annals of Oncology | 2017 | 296 |
| Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study | Journal of Clinical Oncology | 2017 | 211 |
| Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib | Journal of Thoracic Oncology | 2017 | 139 |
| Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival | Journal of the National Cancer Institute | 2017 | 136 |
| The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC | Journal of Thoracic Oncology | 2017 | 132 |
| The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer | Cancer Research | 2017 | 96 |
| Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer | Journal of Thoracic Oncology | 2017 | 82 |
| Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers | Science Translational Medicine | 2017 | 62 |
| Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. | Journal of Clinical Oncology | 2017 | 60 |
| Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study | Lancet Respiratory Medicine,the | 2017 | 56 |
| Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer | Journal of Thoracic Oncology | 2017 | 55 |
| Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer) | Annals of Oncology | 2017 | 51 |
| Circulating MicroRNA-125b Predicts the Presence and Progression of Uremic Vascular Calcification | Arteriosclerosis, Thrombosis, and Vascular Biology | 2017 | 41 |
| Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review | Cancer Research and Treatment | 2017 | 41 |
| Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review | British Journal of Cancer | 2017 | 38 |
| Trends and Outcomes of Surgical Treatment for Colorectal Cancer between 2004 and 2012- an Analysis using National Inpatient Database | Scientific Reports | 2017 | 38 |
| Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting | Liver Cancer | 2017 | 36 |
| Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC | Lung Cancer | 2017 | 31 |
| EGFR-targeted micelles containing near-infrared dye for enhanced photothermal therapy in colorectal cancer | Journal of Controlled Release | 2017 | 31 |
